Devon Zastrow Newman
15 IP cases indexed. Covers patent matters.
Cases Presided Over
15 cases indexed | Page 1 of 1
Guardant Health, Inc. v.Cold Spring Harbor Laboratory
Guardant Health’s IPR against the ’013 single‑cell sequencing patent resulted in the Board finding all 28 claims unpatentable as obvious over prior publications by Linnarsson and McCloskey. The petition’s obviousness arguments were accepted and the patent owner’s defenses were rejected.
GE Healthcare Ltd. et al. v.The Johns Hopkins University et al.
GE Healthcare Ltd.'s Post-Grant Review petition against The Johns Hopkins University was instituted by the PTAB, focusing on obviousness and statutory defects. The Board acknowledged strong arguments regarding combining prior art (US-633/Meletta with Jansen) and potential lack of enablement for radiopharmaceutical claims.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding no reasonable likelihood of prevailing on grounds of anticipation (102), obviousness (103), or written description (112). The Board upheld the validity of the challenged claims in spatial omics/assay systems technology.
r-pac International Corporation v.Adasa Inc
The PTAB denied R-pac International Corporation's IPR challenge against Adasa Inc.'s RFID patent, finding that the prior art presented was cumulative to references already before the Office. The denial was based on Petitioner failing to show material Examiner error under Section 325(d).
Pascal Technologies v.Cambridge Enterprise Limited et al.
Pascal Technologies and Cambridge Enterprise Limited, along with two universities, settled their IPR dispute over U.S. Patent 11,230,656. The Board terminated the proceeding and treated the settlement agreement as confidential business information.
Pascal Technologies v.Cambridge Enterprise Limited et al.
Pascal Technologies successfully secured institution of its Inter Partes Review (IPR) against the '656 patent, challenging claims related to barocaloric cooling agents. The Board adopted a broad interpretation of 'organic material,' supporting the Petitioner's argument that the claimed invention is unpatentable over prior art references like Mañosa and Patel.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully petitioned to institute IPR proceedings against The Johns Hopkins University regarding anti-cancer immunotherapy claims. The Board found sufficient evidence that the MSI-H Study Record anticipates key claims, warranting further trial on grounds of anticipation and obviousness.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB issued a Final Written Decision finding that claims 1-8 of the patent were unpatentable. The Petitioner successfully demonstrated that the MSI-H Study Record (MSR) anticipates and renders obvious most challenged claims under both § 102 and § 103. The Board ruled that the Patent Owner's objective evidence of non-obviousness was insufficient to overcome these findings.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB issued a Final Written Decision finding that all seven claims of the patent were unpatentable. The petitioner successfully demonstrated anticipation (102) and obviousness (103) based on the MSI-H Study Record, which was deemed prior art despite arguments regarding experimental use exceptions.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB issued a Final Written Decision finding multiple claims of the '975 patent unpatentable. The petitioner successfully demonstrated that the claimed methods and drug characteristics were anticipated (102) or rendered obvious (103) by prior art, primarily the MSI-H Study Record (MSR).
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully challenged The Johns Hopkins University's patent claims regarding MSI-H cancer treatment, leading the PTAB to institute proceedings. The petitioner argued that the claimed methods were anticipated by or obvious over existing prior art, including the MSI-H Study Record and various medical literature.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully petitioned to institute IPR proceedings against The Johns Hopkins University regarding a patent on immunotherapy methods. The Board found reasonable likelihood of unpatentability under both 102 and 103, primarily based on the MSI-H Study Record.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB issued a Final Written Decision finding all 38 claims of the '491 patent unpatentable. The Board construed "in response to" as requiring a causal link between MSI-H/dMMR determination and treatment, which led to a finding that the MSR anticipated and rendered obvious the challenged claims.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB found all 30 challenged claims unpatentable by anticipation (102) and obviousness (103). The Petitioner successfully argued that the MSI-H Study Record anticipates the claimed methods for treating non-colorectal MSI-H cancers.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
The PTAB found all 36 challenged claims unpatentable by both anticipation (35 U.S.C. § 102) and obviousness (35 U.S.C. § 103). The Board concluded that the MSI-H Study Record inherently anticipates the claimed methods, including those requiring pre-treatment testing for microsatellite instability high or DNA mismatch repair deficient status. This decision significantly weakens the patent's validity in the context of oncology and immunotherapy.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.